Abstract:Background: One of the most common and efficient methods for detecting mutations in genes is PCR amplification followed by direct sequencing. Until recently, the process of designing PCR assays has been to focus on individual assay parameters rather than concentrating on matching conditions for a set of assays. Primers for each individual assay were selected based on location and sequence concerns. The two primer sequences were then iteratively adjusted to make the individual assays work properly. This generally resulted in groups of assays with different annealing temperatures that required the use of multiple thermal cyclers or multiple passes in a single thermal cycler making diagnostic testing time-consuming, laborious and expensive.These factors have severely hampered diagnostic testing services, leaving many families without an answer for the exact cause of a familial genetic disease. A search of GeneTests for sequencing analysis of the entire coding sequence for genes that are known to cause muscular dystrophies returns only a small list of laboratories that perform comprehensive gene panels.The hypothesis for the study was that a complete set of universal assays can be designed to amplify and sequence any gene or family of genes using computer aided design tools. If true, this would allow automation and optimization of the mutation detection process resulting in reduced cost and increased throughput.Results: An automated process has been developed for the detection of deletions, duplications/insertions and point mutations in any gene or family of genes and has been applied to ten genes known to bear mutations that cause muscular dystrophy: DMD; CAV3; CAPN3; FKRP; TRIM32; LMNA; SGCA; SGCB; SGCG; SGCD. Using this process, mutations have been found in five DMD patients and four LGMD patients (one in the FKRP gene, one in the CAV3 gene, and two likely causative heterozygous pairs of variations in the CAPN3 gene of two other patients). Methods and assay sequences are reported in this paper.Conclusion: This automated process allows laboratories to discover DNA variations in a short time and at low cost.

Automated Identification of Germline Mutations in Family Trios: A Consensus-Based Informatic Approach

Automated Identification of Germline de novo Mutations in Family Trios: A Consensus-Based Informatic Approach

A Gradient-Boosting Approach for Filtering De Novo Mutations in Parent-Offspring Trios

mirTrios: an integrated pipeline for detection of de novo and rare inherited mutations from trios-based next-generation sequencing.

Systematic evaluation of de novo mutation calling tools using whole genome sequencing data

TRGT-denovo: accurate detection of tandem repeat mutations

A Bayesian framework for de novo mutation calling in parents-offspring trios

Hidden Biases in Germline Structural Variant Detection.

Capturing All Disease-Causing Mutations for Clinical and Research Use: Toward an Effortless System for the Human Variome Project

Interlacing Personal and Reference Genomes for Machine Learning Disease-Variant Detection

Automated DNA Mutation Detection Using Universal Conditions Direct Sequencing: Application to Ten Muscular Dystrophy Genes

Increased Sensitivity of Diagnostic Mutation Detection by Re-analysis Incorporating Local Reassembly of Sequence Reads

TRGT-denovo: accurate detection of de novo tandem repeat mutations

Genotype Calling and Haplotyping in Parent-Offspring Trios

An Integrated Approach for Copy Number Variation Discovery in Parent-Offspring Trios.

Automated validation of genetic variants from large databases: ensuring that variant references refer to the same genomic locations

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Bioinformatics of germline variant discovery for rare disease diagnostics: current approaches and remaining challenges

BRCA Testing by Single-Molecule Molecular Inversion Probes

Somatic Point Mutation Calling in Low Cellularity Tumors

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing